Alert

Recommended Alerts

Sign Up For Alerts

CMS Issues Final Rule Redefining Medicare Part D “Negotiated Price” As Pharmacy’s Lowest Possible Reimbursement

On April 29, 2022, the Centers for Medicare & Medicaid Services (“CMS”) issued a final rule revising the way Medicare determines the “negotiated price” (i.e., the price upon which beneficiary cost-sharing is based at the pharmacy counter) under Medicare Part D.

Read More

U.S. District Court for the District of Massachusetts Holds Pharmaceutical Companies Not Required to Disclose FDA Inspectional Observations Made on Form 483

Practices: Life Sciences, Corporate & Securities Litigation, Securities & Public Companies Industries: Biotechnology & Pharmaceuticals

Printer-Friendly Version

Cookie Settings